Parkinson’s Disease Drugs Market Size (2022-2030) Share,

Pune, Oct. 12, 2022 (GLOBE NEWSWIRE) — According to the latest report published by Growth Plus Reports, the global parkinson’s disease drugs market is expected to clock US$ 9.43 billion by 2030 and to grow at a CAGR of 7.80% during the forecast period. This exclusive information is published by Growth Plus Reports in its report titled “Parkinson’s Disease Drugs Market – Global Outlook & Forecast 2022-2030”

The global Parkinson’s disease drugs market has been analyzed from four perspectives: drug class, route of administration, end-user, and region.

Speak to our Analyst to Understand the Impact of COVID-19 on Your Business: https://growthplusreports.com/inquiry/speak-analyst/parkinson’s-disease-drugs-market/7869

Market Driver

The key market drivers for the global Parkinson’s disease drugs market are the prevalence of the disease, large unmet needs for effective treatments, and anticipated commercialization of novel therapeutics. Age is a major factor contributing to the prevalence of Parkinson’s disease. People over 50 years are at high risk of developing Parkinson’s disease. Aging leads to the loss of neurons in the substantia nigra, a part of the brain. Damage to neurons in the brain results in the fall of dopamine, which produces symptoms of Parkinson’s disease. Dopamine is responsible in sending messages to the part of the brain that controls actions and coordination.

Excerpts from ‘by Drug Class’

Decarboxylase inhibitors, dopamine agonists, monoamine oxidase type B (Mao-b) inhibitors, and catechol-o-methyltransferase (COMT) inhibitors are the four drug classes that make up the major market segments. Among such major drug classes, decarboxylase inhibitors have dominated the market. The decarboxylase enzyme is responsible for the breakdown of levodopa, which is further responsible for initiating dopamine activity. Decarboxylase inhibitors act on this activity resulting in a high concentration of levodopa in blood-brain barrier. Other…